From: Outsider Club <ww-eletter@angelnexus.com>
Date: Tue, Sep 29, 2015 at 5:23 PM
Subject: Deadly Disease Killing Thousands of Pets Daily
To: pascal.alter@gmail.com
 Having trouble viewing this issue? Click here. New Breakthrough Could Save 300,000 Dogs From Certain Death... Every Year
Hi, this is Nick Hodge. What I'm about to share with you is a little uncomfortable for me. Frankly, I don't like to reveal too much about my personal life, especially something this tragic. But in light of what I've recently discovered — and its implications for your family — I've decided to share it with you. The story you're about to hear could save the life of 300,000 dogs every year... including yours. And it could also make you a significant amount of money before 2015 is over... enough to secure your financial future. So I urge you to read this time-sensitive message to the end, whether you own a dog or not. It all began last year, when a fatal disease killed my beloved chocolate lab, Mocha.
This same disease claims 300,000 dogs every year. And there's a 50% chance you might lose your dog to it. It could strike instantly, in the blink of an eye, without notice. Just like it recently claimed my best friend Mocha. Now, forgive me if I sound a bit somber. While I'm no longer mourning, I still have trouble talking about it. You see, Mocha was more than just a friend; she was a family member. At least my family thought of her like that. I grew up on a farm, and there weren't a lot of kids around. So sure enough, I spent most of my time with Mocha.
We hunted, fished, played ball, and hung out in the barn. Some of my fondest childhood memories come from our times together. In fact, it's hard to imagine my childhood without her. I used to pretend I was taking her out to pee when she was a puppy so I could smoke cigarettes. Boy stuff like that.
But recently, at the age of 15, she came down with a fatal disease... one that now afflicts one of every two dogs. By the time we discovered it, it was too late for Mocha. No treatments were available. We were powerless to stop it. I was heartbroken. Devastated. I can't compare it to anything else. If you've ever lost a dog or family pet, you know the feeling. Sure, eventually life moved on. But I couldn't help but think if something more could have been done to save her. Why not? I mean, dogs are man's best friend. Many people see their dogs as companions, children, family members. They give us so much. Why not do everything in our power to save their lives?
You see, the same disease that took my dog's life has become an epidemic. It's now the number one killer of dogs. More than diabetes and heart disease. According to Science Daily, one in two dogs will contract this disease at some point in their lives. Out of those, over 50% will die... unnecessarily. The numbers are even scarier when it comes to popular breeds like Golden Retrievers, with 60% dying from this killer. And other breeds are at similar risk — dogs many Americans own like German Shepherds, Poodles, and Labrador Retrievers (just to name a few). All told, 300,000 dogs will die from this disease in 2015. And even though Americans have shelled out $2 billion per year for treatment, little could be done to save them. No cure existed. The situation seemed hopeless.
After Mocha died, I kicked off a year-long investigation... An investigation into a life-saving treatment for this deadly disease, what's known as canine lymphoma — the number one form of cancer in dogs. And what I uncovered is better than I ever expected... A breakthrough drug has been developed, and it has the potential to save as many as 300,000 dogs every year from this "instant killer." It's so powerful that the New England Journal of Medicine found it can "rapidly eradicate a large tumor mass after a single dose." And it's so potentially lucrative that it could multiply your money 25-fold... before 2015 is over. As you're about to see...
This treatment builds upon recent innovations in human oncology to eradicate canine cancer. You see, over the past two decades, scientists have developed what are known as immunotherapies — therapies that trigger our immune system to kill cancer cells. One of these treatments uses something called monoclonal antibodies. And it's already proven it can treat lymphoma in humans. Basically, it harnesses molecules that latch onto cancer cells and signal where your immune system should attack, giving your antibodies sight where they were missing. This revolutionary treatment first came to market with the drug Rituxan. Since then, it's radically changed the lives of many cancer patients. The National Cancer Institute says that Rituxan "revolutionized cancer care," and the mortality rate for non-Hodgkin's lymphoma has dropped 3% every year as a direct result. In fact, 13,897 published studies prove that patients who receive this drug...
All without radiation, chemo, or surgeries. So we know this works in humans... what's known as "proof of concept" in pharma circles. But the real question is, will it work on dogs? That's what one innovative team of scientists set out to find. They worked for years to tailor the same therapy specifically to treat canine lymphoma. And now they've done it. For the first time ever, they've developed a REAL cancer treatment for dogs... one proven to lengthen survival time by 400%. It's a historic breakthrough that's giving hope to millions of American families with dogs.
Imagine if you could 100% spare your dog from agonizing treatments and pain... Now imagine doing that for a fraction of the cost of normal pet care. This new therapy is making all that a reality. If you own a dog or any pet, how much would you pay for a treatment like this? After all, many Americans — like me — think of their dogs as family members. Fewer young people in their 20s and 30s are having children. Instead, they're adopting dogs or cats and treating their pets like surrogate kids. In fact, new research shows we're hardwired to think this way. A recent study published in Science Magazine found that a similar chemical reaction takes place in the brain during owner and pet bonding as to that of parental bonding with a child. Researchers found increased oxytocin levels in our brains when we extended a long gaze at our pets... remarkably similar to the brain's reaction of a parent to a child. In other words, our pets are like our children. And just like with our children, we'll do just about anything to keep them happy, healthy, and living longer. That's why dog owners are shelling out $20,000 a pop for chemotherapy... And why industry estimates report 150,000 dogs receive chemo each year. All told, vet cancer costs now run as high as $2 billion annually. Mind you, that's just to give our pets nine more months to live! "Pet owners across the country are forking over thousands — and even tens of thousands — of dollars for treatments like this." — Market Watch But what if we could give our dogs many more years to live without dangerous side effects? How many more people would seek treatment? How much more would they spend? It's not hard to see that while sales of this new cancer breakthrough are a mere $767,000... The story moving forward is completely different. As I'm going to show you today...
And One Company Just Secured a Monopoly on it" It not only has the potential to save as many as 300,000 dogs every year... But it could put $5,000 in your pocket for every treatment administered and every life saved. On January 5, 2015, the USDA approved the first of these treatments. Since then, over three-dozen clinics have placed their orders for it. And dozens more are banging on the door for shipments. As we speak, it's replacing chemo as the "first-line" therapy... moving to the frontlines of the billion-dollar pet cancer market. Now, one tiny Kansas City-based company has secured 100% of the profits. While this firm's market cap is $455 million... Its sales are a mere a $767,000 per year... And it only trades for $12. That's all about to change. Thanks to its first-mover advantage on this untapped market and its wide range of innovative therapies, it's emerging as the number one player not just for pet cancer... But for the entire $30 billion pet health industry. You see, this company has 18 cutting-edge treatments in the pipeline that will revolutionize standard care for every pet disease imaginable. Everything from diabetes... to chronic pain... to osteoarthritis. All targeted specifically to dogs and cats. And all lined up for approval THIS year. That's why this company won the Best Pipeline 2014 Award for "the depth of its pipeline and the potentially lucrative opportunity the firm faces." But I think that's an understatement. Until now, only four other pet-specific therapies have been invented... and none of them received approval. Let me repeat that: Only four other medical therapies have EVER been invented for pets! Again, this company has 18 pet-specific treatments — over four times that much. So I'm not exaggerating when I say this company is about to dominate a truly untapped market, one with massive upside potential. It's absolutely unprecedented.
But here's the best part, something most investors don't realize. A weird legal loophole that allows this company to sidestep the FDA. And what I think makes this such an urgent opportunity, one you need to jump on now while it's early... Unlike human drugs, pet treatments are under the jurisdiction of the USDA (not FDA), which quickly approves animal medicine. This means no massive regulatory expenses... No long waiting periods... And no red tape. So this is all coming down the pipeline faster than you can imagine. The USDA is about to sign off on each of these therapies over the next few months. Each time, this stock will soar, potentially doubling your money over and over. If you don't move today, you'll miss out on this tiny firm's astronomic rise to the top of the $30 billion pet health market — America's fastest-growing industry... And the potential to grow your money five... 10... 15... 25 times over — maybe more — before 2015 closes out. In fact, every $1 you invest could not only return you $10, $15, $20, or more... But also save a dog's life. It's a truly a rare opportunity... a chance to get rich while supporting a breakthrough that does so much good, whether for your own family's dog or for the lives of 77 million dogs in America. Again, its current sales are a mere $767,000. But its projected sales on the current cancer market alone are $2 billion. That's a sales surge of 260,756%! But you need to get in early, before thousands of clinics around America and the world put in their orders. I'll share with you all the details of this historic opportunity in a moment, including the inspirational company on the bleeding edge of this technology. I'll give you the ticker symbol, company profile, and everything you need to know about its breakthrough cancer treatment. But exactly how much money could this make YOU? The numbers say it all...
In 1988, 56% of American households owned a pet. Today, it's 70%. In 2015, they'll spend $60.5 billion on their pets. Precisely half of this spending — a whopping $30 billion — will go to cover their health care, including veterinary visits, drugs, and surgeries. That's why the Wall Street Journal calls this market: "A prize for medicine-makers." As Bloomberg reports: "After consumer electronics, pet care is the fastest-growing category in retail." And David Krempa, equity analyst for Morningstar, says: "[The animal health industry] is a really attractive business to be in, more so than human pharma." Several pet pharma plays have even soared for life-altering gains. For example... Skystar Bio, an animal vaccine developer, soared 542% in just 12 months.
Henry Schein, a vet supplier, surged for 2,558% gains...
And PetMed Express, the online pet medicine retailer, has handed investors staggering returns of 15,633%.
Gains like this are great... but they're really just the beginning.
The New York Times even says this company's potential growth matches that of the early biotech companies for human medicine, comparing these new pet drugs "to those that have revolutionized the treatment of diseases like cancer and arthritis in people." And if you've followed the biotech growth story, you know many of these cutting-edge companies have generated historic gains... Like Jazz Pharmaceuticals, which soared for 28,238% gains in only four short years.
Just a tiny $1,000 stake could have handed you a $283,380 windfall. And if you invested as little as $3,500, you'd be sitting on a million-dollar retirement nest egg. There's Questcor Pharmaceuticals, which has the blockbuster M.S. drug Athcar. The market for Athcar surged from $100,000 in 2001 to $1 billion in annual sales by 2014. As a result, Questcor has skyrocketed for 45,090% gains since 2007.
Biogen, the company that brought Rituxan to market, skyrocketed for unbelievable 134,433% returns.
And Amgen surged for 204,185% gains — the largest returner I've ever seen in the markets.
Imagine every $100 invested turning into $204,185. It's so good that you could have become a millionaire, even if you had only started with $500! So America's biotech bonanza has not only produced the most cutting-edge developments in medical history... But it's also returned some of the biggest profits in financial history. Now, if you missed out like most investors, don't worry. Because I've got good news... I think this new pet biotech sector is offering investors the same ground-floor opportunity. It's a whole new field of untapped medicine, much like biotech in the earlier stages. And this tiny company could give you a shot at seeing these kinds of returns again. Again, its current sales are only $767,000. But this new cancer breakthrough could rocket revenue all the way to $2 billion. That's a sales surge of 260,756%. Sales like that have only been seen at the very ground floor of the biotech boom. Yet that only hints at its true growth potential. After all, the $2 billion sales projection is based on the current dog cancer market. Once people see there is a safe, affordable, and effective treatment available, it's not hard to see the market could rapidly double or triple. After all, 6 million dogs are diagnosed with cancer each year. Not to mention that dogs are susceptible to increasing rates of cancer. They're living longer and getting the same diseases as humans. The environment is also causing higher pet cancer rates. If even a fraction of dog owners seek treatment at a going rate of $10,000... We're looking at $15 billion in sales. In short, there is NO limit to this market's upside potential or just how much money this company could hand investors. The best part is, I think it could make investors rich even quicker than the biotech boom. You see, the early biotech players had to jump through FDA hoops, spending millions on research, before they saw their drugs hit the market and deliver investors these staggering returns. But as you've already seen, pet medicine is completely different.
As I mentioned before, it's under the jurisdiction of the USDA, not the FDA. Why does that make such a big difference? Well, the FDA has specific guidelines that drive up the cost and time to bring a new drug to market. It's these guidelines that play a role in making our meds so expensive in the first place... And why it's so difficult for companies to get new life-saving medications to markets. But these same guidelines simply don't apply to the USDA. It's a weird anomaly with three life-changing benefits for pets and investors:
In 2015 alone, this company has a dozen new pet medications lined up for USDA approval. Cutting-edge therapies for pain... arthritis... and diabetes. Treatments that are about to become "first-line" for veterinary offices everywhere... moving this company to the forefront of the $30 billion pet health market — one of America's fastest-growing markets. It's all going down within the next 12 months. That's why major institutions are loading up on shares.
In fact, 86 of Wall Street's top hedge funds just skyrocketed their positions. Last quarter, they owned 957,000 shares. Now they've locked in 28 million shares. That's an incredible 2,973% boost of ownership within just three months. The hedge fund Franklin Resources, for instance, recently bought 10.5% of the available shares. So why is the smart money buying shares like hotcakes? Simple... They see that 2015 is a transformative year... They see all the drugs releasing top-line results... And they see the USDA is about to approve them, handing this tiny company the dominant share of a $30 billion industry. That means you need to move fast if you want to secure a position on the ground floor. Could this company soar 28,000% like Jazz Pharmaceutics? Or 45,000% like Questcor? Or 134,000% like Biogen? Or 204,000% like Amgen? Listen, I can't guarantee you those kinds of returns. Nobody can. But I can tell you this: When you look at the facts... When you consider this pet disease market is untapped territory, one poised to repeat the historic growth of human biotech... When you consider this company is a first-mover, with advanced treatments for every major pet disease... When you consider it's the first to receive USDA approval for a dog cancer drug... When you consider this company's line of patents securing it a monopoly on the pet health market... When you look at the desperate demand for its new treatment... And when you look at potential sales growth of 260,756% on just one of these medications... You can only come to one conclusion. This opportunity is so extraordinary that you can't miss it. But first things first: How can I be so certain this therapy works?
Well, the good thing is we don't have to guess. This treatment is already making a difference in the lives of pets and their owners. Michael Graner, PhD, a CU Cancer Center investigator and associate professor of neurosurgery at the CU School of Medicine, is one of the earliest pioneers of this treatment. It began when his Great Dane named Star, age 12, suddenly collapsed during a coughing fit. She was diagnosed with lung cancer. The prognosis? Only six to 27 days. Star was well past the age when she could've tolerated chemotherapy or radiation. "With that diagnosis, chemotherapy has only a 10-15 percent response rate and she was old — with her prognosis and the drug side effects let's just say chemotherapy wasn't viable. We didn't want to make her any sicker," Graner says. So Graner turned to his specialty: immunotherapy. He injected a safe, simple dosage of this immunotherapy to attack her cancer tumors. And instead of dying within days or weeks, months started rolling on by. "The important thing to us was her quality of life was really good," said Graner. "It was really simple and it certainly didn't hurt." 44 weeks later, Star showed aggressive progression of the disease, and the family had her put down. But this treatment gave her almost a year, compared to four weeks — the original prognosis. And this is only one example... According to veterinary oncologist Nathan Cox, the average lifespan for dogs after chemo is only six months. But with this new immunotherapy, says Cox, "we have dogs living out past three to four years, so it's more than doubled survival times." "It's really changed the game," Cox continues. "It's been more effective than chemotherapy has been for dogs." And he even went so far as to say...
Take the case of Grizz, a St. Bernard, who came to Dr. Cox with a very aggressive melanoma — one that was spreading so quickly it could have killed the dog in just days. Two years after receiving the treatment, Grizz is happy, healthy, and normal. Cox reports, "I'm thrilled with his progress... he's doing beautifully." So it's no wonder that when doctors told one dog owner, Sam Weinberg, that this breakthrough cancer treatment was the only hope for his dog, he didn't hesitate to jump on the opportunity. "She's basically like family," he said. "I don't have children, so she's like my kid. When they said that's her only chance, it's 100 percent fatal, I just said, 'Let's do it.'" There are tens of thousands of pet owners just like Sam... people who will spare no expense for their beloved pets. Can you see why this is promising to change the lives of so many dogs and their owners? And why the company at the bleeding edge of this therapy will make so many investors rich? So you can start profiting immediately, I've assembled a cutting-edge prospectus with everything you need to know about this opportunity. It's called, "Get Rich from the $30 Billion Pet Health Boom." Inside, you'll find all the details on this groundbreaking play, including its name, ticker symbol, company profile, and the pipeline of treatments lined up for government approval. Every bit of lucrative information could help you turn this under-the-radar boom into the financial windfall of your life. In just a moment, I'll show you how to get your hands on this unique market research absolutely FREE. But it's possible you might still be wondering if people will really pay tens of thousands to save their dogs from cancer... The good news is they won't have to. You'll see why in a moment... Why this virtually guarantees almost every dog with cancer will receive this treatment... And why this means potentially millions in your pocket. In fact, as a bonus, I'll share with you a second way to play this explosive market... A recent $8 IPO that's piggybacking on the surge in pet health spending. But before I reveal all the lucrative details, I think the REAL question is...
America is witnessing an unprecedented wave of spending on pets. Entirely new industries are emerging to meet the needs of what CNBC calls the "new pet consumer class." And Bloomberg calls this explosive trend the "pet economy." Take Denver, my current dog, a purebred Blue Pit Bull. He's torn both knee ligaments, and each time, I ponied up $6,000 for titanium implants in the bone. I have X-ray pictures of this. I also have thousands of pictures, thanks to my wife, of him since he was a puppy. He's five now and the epitome of this new "pet consumer class." He gets venison and liver cooked for him, outfits, high-end treats... you name it. Here's Denver dressed in a luxurious feather boa:
And in his own Super Bowl jersey:
And I'm far from alone. Again, pet owners are forking over $60 billion in 2015 for their pets. And when you starting dissecting the numbers, they're absolutely shocking... Take pet grooming, boarding, training, and sitting services. In 2014, the market was $4 billion. This year, it's expected at $5.4 billion, according to the American Pet Productions Association. That's a 35% sales surge in one year just for pet luxury treatment. But we're not only treating our pets better... We're feeding them better, too. Consumer surveys by market researcher Mintel found 79% of pet owners agreed the quality of their pets' food is as important as their own. The numbers show it. Pet food sales have soared 100% since 2002. The market is now $22 billion.
But most of that money comes from skyrocketing demand for organic pet foods. In 2013, Americans spent a record-breaking $4.6 billion on natural food for their dogs and cats. This was unthinkable just a decade before, when the market was only $14 million. That's an incredible 29,285% sales surge. I've never seen a boom like it. The real winner of this trend? PetSmart and its investors, who have seen 3,061% gains in a very short time span.
Neogen Corp., which inspects pet food for safety, has gone off the charts with 12,900% gains.
However, the biggest indication of the surging pet market is the gifts we're buying our animals. According to the National Retail Foundation, people are expected to spend up to $350 million just on Halloween costumes for their pets.
Spending for Christmas presents for pets is rising twice as fast as spending for human presents. During November and December, the average shopper is expected to spend $30.43 on pet gifts, up 14.2% from the same period a year earlier. In comparison, spending on family is forecast to increase 6.5% to $459.87, and buying for friends is predicted to rise 6.7% to $80. For Valentine's Day, people are projected to spend $703 million on their pets. Sounds ridiculous, I know. But my point is simple... If people are willing to pamper their pets with costumes, organic food, and luxury grooming, providing better care than they do for themselves or even their family members... Then cancer treatment is a no-brainer. That's why...
Dog owners are happy to pay the astronomically high tab for chemo, even if it means only a few more months with their friends. For example...
Dr. Addison's 11-year-old mixed breed, Kaya, was diagnosed with leukemic lymphoma. Addison, a vet herself, had treated Kaya with six rounds of chemotherapy. That's a total of $60,000. Like humans do, Kaya experienced loss of appetite, loss of hair, vomiting, and diarrhea. For all of that, she lived 33% longer than most dogs — 16 months. As Addison reports, "Looking back, I have no regrets in treating her cancer with chemotherapy and we were blessed to have been able to care for her after all she has given to my family and I."
Jack Ely discovered his dog Inca had an aggressive form of cancer, so he turned to a specialist in veterinary oncology to try to save her. Her treatment included two bouts of chemotherapy, but Inca died 18 months later. All told, Ely spent around $25,000. "She was worth every penny and I'd do it again tomorrow," Ely said of his beloved Chocolate Labrador.
Jack Raney's dog Newman, a 9-year-old mixed breed he rescued from the shelter, spontaneously developed a golf ball-sized tumor. The diagnosis? Brain and lung cancer. Jack spent $10,000 to treat Newman with chemotherapy... and the results were horrible. Newman started slowing down, sleeping more and walking less. He couldn't eat. His vision, hearing, and memory started to take a turn for the worse. Within a year, Newsman passed in spite of additional treatments. But even though Americans are sparing no expense for their pets... Even though they're already shelling out $30 billion a year for their pets' health care, including $20,000 a pop for ineffective chemo treatments... That won't be the case for this new cancer breakthrough. Not at all. In fact, they'll pay almost nothing out of pocket for it, or for any of this company's other treatments. All thanks to the rise of a whole new billion-dollar market: the pet health insurance industry.
And Why It Guarantees This Cancer Breakthrough Pet health insurance raked in $331 million in 2009. This year, it's bringing in $750 million in premiums. By 2020, it's projected to hit $1 billion... an average double-digit market growth year over year. The surge in pet ownership is one thing behind the growth of this new market. Sky-high vet and drug costs, like you've already seen, are behind the soaring market, too. But the number one cause for the market's explosive growth is... ObamaCare. See, the Affordable Care Act has forced employers to look more closely at their benefits in order to stay competitive. One focus group puts pet insurance in the top three benefits most requested by employees. That's why a number of the nation's largest companies now offer pet insurance, including:
But that's just for starters. As the Chicago Business Journal writes, "These companies are a few among a rapidly growing number that offer pet insurance to employees as part of their benefits package." In fact, one in three Fortune 500 companies now offer pet insurance to their employees. Some are even covering part or 100% of premium payments. In short, this could soon be as common as regular employer health insurance coverage. In England, 25% of pets are insured. In Sweden, it's 50%. I think the U.S. is heading to similar numbers, especially as a number of reputable insurers are coming to market. My point is, the canine cancer breakthrough — and the company behind it — is guaranteed at least $2 billion in sales. But that's just from the current market of dog owners who are seeking treatment. Considering this therapy is far more effective and safer than chemo and far less expensive... And considering so many more pet owners are receiving or buying pet health insurance... The market for dog cancer care could double, triple, or quadruple... easily. And this one company is positioned for a monopoly on this explosive market. Again, that's just for the pet cancer market. This company has a wide range of innovative breakthrough therapies covering every form of pet disease... Which is why it's positioned to dominate the $30 billion pet market. It's also why it could multiply your money five, 10, even 15 times over... And why I'm including it in my new research kit...
Look, I want dogs everywhere to live longer, healthier, and happier lives. After all, they bring so much happiness and so much love to so many people. Unfortunately, more dogs are dying every year from the ravages of cancer. Six million dogs were diagnosed with cancer in 2014. It's become an epidemic. We have to stop it before it gets worse. That's why I'm putting down big money. It's my small part to ensure this breakthrough reaches everyone. While I know I'll see my investment return in spades, and that's great and all... It's not just the money I'm making from this development. It's that every dollar could possibly save the life of a dog, whether it's a family member's or friend's. I know I wish this treatment were available before my dog Mocha passed. Now, hundreds of thousands of pet owners every year can have the opportunity to save their dog's life... And it's all thanks to this cutting-edge company. Again, I've included all the details on this pet biotech pioneer in my new research kit, "Get Rich from the $30 Billion Pet Health Boom." Inside, you'll find the company's name, ticker symbol, and profile. Whether or not you own a dog, I urge EVERYONE to jump on this quickly. It could secure your financial freedom, while doing so much good for millions of families. Remember, 70% of Americans own a dog or cat. You're doing your part to ensure either your loved one or someone else's gets the treatment they deserve. In return, you could make a ton of money — enough to retire early. Plus, as a special thank you for viewing this presentation, I'm throwing in a bonus pick. And although I'm not adding it to my official portfolio, it could make you a killing on the pet health insurance boom — one that, as you've just seen, is making money hand over fist.
It's a new $8 IPO based in Seattle. And this pet insurer is witnessing unstoppable growth. The number of pets enrolled has surged from 156,000 in 2013 to 250,000 — growth of 60%. Its revenue has done even better... From $19 million in 2010, it's projected to reach $150 million this year — a remarkable 689% surge in sales. The company is aiming for $1 billion in annual sales. I think it can get there... and soon. See, the bulk of its revenue is generated from a growing client base of subscribers. The subscriber retention rate is pretty solid at 88%. So they are very loyal. And there's a good reason for that, too... The company offers attractive plans with 90% coverage and no payout limits. So it has reliable, recurring revenue that's growing quickly as the number of pets enrolled surges. While multiple insurers are emerging in this new space, as health spending soars, I think this play is solidly positioned as a dominant player within this market... with a good chunk of market share. This year, it's up 58%... and I think it's only the beginning as the pet insurance market takes off. $17 a share is not out of the question for 2015. You could be looking to at least double your money before the year is out. Again, all the details are in my new report: "Get Rich from the $30 Billion Pet Health Boom." And you can claim this unique market research for FREE today. All I ask in return is that you take a test drive of my research advisory service, Early Advantage, completely risk-free.
Again, my name is Nick Hodge. I'm an investment analyst here at Angel Publishing in Baltimore, Maryland. I'm also editor of Nick Hodge's Early Advantage, the resource for big profits from little-known breakthroughs and disruptive technologies in energy, electronics, technology, agriculture, and more. No sector is off limits. In just the past few years, I've brought investors massive, rapid-fire gains from companies in multiple sectors, such as those you see here:
And the list goes on and on. I simply don't have the time to list all of my big-time winners here. But know this: Off of just one of my recommendations, you could make the type of money that could change your portfolio... or even your life. How do I know? It's already happened. One guy by the name of Dan Leopold wrote to me about one of my recent recommendations...
I've had to redact the stock name there because it's an active play that's still making people money, and it wouldn't be fair to those currently holding positions. Donald McMillan shared his story, too:
And Anthony Reymond recently wrote me to say:
But my favorite is from Tom Donaldson, who made nearly half a million dollars on a single trade:
So as you can see, I continually provide the potential for huge gains. And I can tell you this... It takes a lot of hard work and boots-on-the-ground research to maintain the success I've experienced. Whether it's flying out to California and speaking with an aquaculture expert to get the inside details on a world-changing medical discovery...
Or taking a tour with Canadian CEOs to uncover the newest intelligence in the world of energy...
Or even interviewing Montel Williams in the hopes of discovering the next 1,000% gainer in the market...
There's not a stone I won't turn over if I think there's money to be made on the other side.
You already know the best way to make a lot of money is to get in the game early — before a company makes news with a major discovery in the mining or energy sector... the creation of some disruptive technology... or breakthroughs in agriculture or health. I'll go to any extent I feel is necessary to make sure things are on the up-and-up before I recommend something other folks might put their money into. I don't simply sit behind a desk, stare at a computer screen, and pick a stock based on some arcane information from an annual report. That's for the no-talent hacks that think they know what they're doing. Not me. I do the real research most analysts don't feel like doing — or can't afford to do. I've been in a three-man helicopter over the Canadian wilderness... stood on the edge of 500-foot-deep mines... and attended $5,000/seat conferences across the country... all in the name of securing the full stories behind the biggest wealth-creating opportunities in the world. You can even say I've hobnobbed with the financial elite...
If you didn't already know, the "other guy" in that snapshot is John Paulson, American hedge fund guru and billionaire. We were both invited to a closed-door investment summit in Puerto Rico recently, and we had a nice little chat. It's pretty obvious these things don't happen for analysts who refuse to leave the office — or get out of bed. But I do it because it's what I love to do. It's what I've always loved to do. Giving readers like YOU the early advantage on any moneymaking or money-saving opportunity available long before the rest of the market catches on. That's what Early Advantage is all about. I've been on the cutting edge for years, discovering major life-changing, moneymaking opportunities that other financial institutions don't cover. Just to give you a better idea:
My research comes with NO RISK and absolutely NO OBLIGATIONS. For 60 days, you'll have the chance to profit from every single one of the winning investments I've shared exclusively with my followers... without risking a single dime. I want you to see for yourself how potentially profitable Early Advantage really could be for you. Simply put, the minute you claim your copy of "Get Rich from the $30 Billion Pet Health Boom," you'll immediately receive 60 full days of unrestricted access to the following:
Within minutes of signing up, you'll receive an email with your password to the Early Advantage website — your ultimate gateway to unheard-of profits in cutting-edge sectors ahead of the crowd.
So how much does all this cost? The short answer is: nothing. I've convinced my publisher to give you a special deal... one we've never offered before. Now, I've seen research services like Early Advantage sell for $10,000 or more. There are also "analysts" on Wall Street who pay thousands for these small-audience subscriptions. Some of these analysts work in hidden niches of the market, making millions per year to research new ways to play upcoming trends. To them, services like mine are a leg up on the competition, and they would happily pay $10,000 or more per year, since it's really a fraction of the cost some "professionals" shell out for research like this. But even though I could see this service going for that much, I know it would be difficult for everyday investors to participate at such high a price... So I asked myself, "What's the absolute minimum I could ask people to pay for this service? What's reasonable? What's fair, considering the fundamental value?" After all, Angel Publishing and Outsider Club are in the publishing biz, and we have to keep the lights on here. That, and many of the companies I recommend with this predictive investment strategy require deep investigation. That last part means I have to travel out to worksites... talk to the geologists and engineers... rub elbows with the people on drill decks and in core shacks... and meet with the CEOs and other executives. So after crunching the numbers, I finally settled on a price of $1,599 per year for this service. At least, that will be the regular price of this service moving forward. It's easy to understand why: One single recommendation could easily pay for your entire subscription. For example, one of my followers, Chris G., recently sent me this note:
Another of my followers, who wishes to remain anonymous, chimed in, "I just renewed Early Advantage. Made $6,000 on one play, so my membership has more than paid for itself. Keep 'em coming!" Another one of my followers, Donald M., said he made a profit of $27,649 last year, as you saw earlier. That's enough to pay for 17 years of my research! Todd S. is up a bit more, saying...
Given these kinds of gains, I'm sure you'll agree $1,599 is a bargain. But you won't have to pay that.
As one of my invited subscribers, I'm prepared to offer you the entire Early Advantage subscription for just a fraction of the cost... In fact, you'll pay 50% less than others pay for 12 months of my profit alerts. That's a HUGE discount off the normal price! Simply click the "Subscribe Now" button below to see your final pricing. I truly believe the $30 billion pet health boom is the single best opportunity I've ever discovered. I want to make absolutely sure you don't miss out on your chance to profit from it. But there's no telling how long this offer will be open, especially considering these companies are small now but could be hitting the mainstream soon. Even if we can at some point reopen this offer, it will likely only be to a handful of people, and it will probably come with the full price tag. It's a truly unique opportunity. Because when I release my next alert, you could be up and running on your own path to becoming... well, much better off financially! Subscribe at the end of this presentation to start receiving your profit alerts each month!
You simply cannot afford to let this opportunity pass you by. Click the "Subscribe Now" button below to receive my latest alert, and you could be on your way to riding the biggest gains of your life. And if you're still not convinced, you have 60 days to decide if my brand-new strategy is really right for you! You have my personal guarantee...
You see, I stand behind every piece of advice, insight, and recommendation I make with 100% confidence. Your complete satisfaction is guaranteed — or your money back! So I want you to go ahead and take a FULL 60 DAYS to have a good look at every breakout company I've uncovered. And then, if for any reason you're not totally thrilled... Just tell us to send your money back, and we'll promptly refund every penny, NO QUESTIONS ASKED. You'll get all the details about the $30 billion pet health care boom... the new canine cancer breakthrough... and the one tiny play about to see explosive 260,760% sales growth. You'll get the exclusive information on the members-only Early Advantage website... all the reports and investment guides... all the recommendations... all the articles and investing tips. And if you join me today, I will give you access to three bonus reports — ABSOLUTELY FREE:
Some folks have shelled out $799 for EACH of these reports, but you won't pay a single cent for them. All three bonus reports are yours FREE when you agree to test-drive Early Advantage for 60 full days starting right now. The intel in just one of these special briefings could easily pay for your membership many times over... And they're yours to keep — no matter what your final decision is. But you must act fast... As you've seen, this canine cancer breakthrough is lined up for USDA approval THIS year. The opportunity is hot. One of these treatments was approved on January 5. Over the next few months, we'll see over a dozen of its treatments get approved. Each time, this tiny stock will double over and over. And by then, it will be way too late. You've seen the charts. You've seen the proof. You've seen the wealth and money. Here's what I suggest you do right now... Click the link below to get started right away. You'll be able to review everything on the next page before your order is final. And remember, this offer is risk-free for 60 days. If you don't like what you see, call us and cancel. But if you're still reading, I don't think you'll need to worry, because I seriously doubt you'll be canceling... Especially when you see what I've prepared for you. Remember, your opportunity for incredible wealth could start immediately with my next alert. I urge you not to delay. I likely won't be able to offer this amazing deal to anyone else after this initial offer expires. Just click below to get started. I look forward to the wealth we'll make together. Call it like you see it,
Nick Hodge
This email was sent to pascal.alter@gmail.com . You can manage your subscription and get our privacy policy here. Outsider Club, Copyright © 2015, Angel Publishing LLC, 111 Market Place #720, Baltimore, MD 21202. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Outsider Club does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it.(...). |
Brak komentarzy:
Prześlij komentarz